KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Debt: 2015-2024

Historic Non-Current Debt for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $166.5 million.

  • BeOne Medicines' Non-Current Debt rose 344.11% to $832.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $832.8 million, marking a year-over-year increase of 344.11%. This contributed to the annual value of $166.5 million for FY2024, which is 15.75% down from last year.
  • Per BeOne Medicines' latest filing, its Non-Current Debt stood at $166.5 million for FY2024, which was down 15.75% from $197.6 million recorded in FY2023.
  • BeOne Medicines' Non-Current Debt's 5-year high stood at $209.1 million during FY2022, with a 5-year trough of $166.5 million in FY2024.
  • Its 3-year average for Non-Current Debt is $191.1 million, with a median of $197.6 million in 2023.
  • Its Non-Current Debt has fluctuated over the past 5 years, first climbed by 16.68% in 2020, then declined by 15.75% in 2024.
  • Yearly analysis of 5 years shows BeOne Medicines' Non-Current Debt stood at $183.6 million in 2020, then climbed by 10.06% to $202.1 million in 2021, then rose by 3.48% to $209.1 million in 2022, then declined by 5.51% to $197.6 million in 2023, then dropped by 15.75% to $166.5 million in 2024.